| 000 | 00914 a2200253 4500 | ||
|---|---|---|---|
| 005 | 20250514023752.0 | ||
| 264 | 0 | _c20020315 | |
| 008 | 200203s 0 0 fre d | ||
| 022 | _a0399-8320 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLemann, M | |
| 245 | 0 | 0 |
_a[What can be expected from biological therapies for Crohn's disease?]. _h[electronic resource] |
| 260 |
_bGastroenterologie clinique et biologique _cNov 2001 |
||
| 300 |
_a945-7 p. _bdigital |
||
| 500 | _aPublication Type: Comment; Editorial; Review | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 |
_aAnus Diseases _xdrug therapy |
| 650 | 0 | 4 |
_aCrohn Disease _xcomplications |
| 650 | 0 | 4 |
_aGastrointestinal Agents _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfliximab |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _ximmunology |
| 773 | 0 |
_tGastroenterologie clinique et biologique _gvol. 25 _gno. 11 _gp. 945-7 |
|
| 999 |
_c11753699 _d11753699 |
||